{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:47:39Z","timestamp":1750686459466,"version":"3.40.5"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To ascertain the efficacy and safety of cladribine, cytarabine, and filgrastim-based regimen in relapsed or refractory (R\/R) AML patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Clinical studies were searched in PubMed, Cochrane Library, Embase data. We selected available factors including complete remission (CR), overall response rate (ORR), overall survival (OS) to evaluate the efficacy, and early death (ED), and adverse events to evaluate safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>15 records with 812 R\/R AML patients were finally included and analyzed using the R software. Subgroups analysis was also conducted. The pooled CR rate for CLAG regimen, CLAG-M regimen, and CLAG combined with any other drugs regimen is 56% (95% CI: 46\u201366), 46% (95% CI: 34\u201356), 44% (95% CI: 26\u201364), respectively. The relapsed and refractory groups showed a CR rate of 68% (95% CI: 53\u201380), and 51% (95% CI: 45\u201358) with CLAG related regimens. As risk grade decreases, the pooled CR rate increases. Regarding the safety for CLAG-related protocols, systematic review was conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The CLAG-related regimen is an effective and safe therapy for R\/R AML patients, CLAG seems to have more superiority than CLAG combined therapy, though further studies including cladribine combination treatment protocols, are still needed to confirm our results further.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034949","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T09:14:34Z","timestamp":1701162874000},"page":"e34949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-1948","authenticated-orcid":false,"given":"Susu","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Hospital of Anhui Medical University, Hefei, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianshan","family":"Tao","sequence":"additional","affiliation":[{"name":"Shaoxing People' Hospital, Shaoxing, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[{"name":"Shaoxing People' Hospital, Shaoxing, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shaoxing People' Hospital, Shaoxing, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[{"name":"Shaoxing People' Hospital, Shaoxing, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"38","article-title":"Acute myeloid leukemia: a review.","volume":"103","author":"Pelcovits","year":"2020","journal-title":"R I Med J (2013)"},{"key":"R2-20250504","first-page":"1051","article-title":"Acute myeloid leukemia [published correction appears in N Engl J Med 1999 Nov 4;341(19):1484].","volume":"341","author":"L\u00f6wenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.","volume":"118","author":"Burnett","year":"2002","journal-title":"Br J Haematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia.","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10428190290006053","article-title":"The search for optimal treatment in relapsed and refractory acute myeloid leukemia.","volume":"43","author":"Robak","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2010-05-260117","article-title":"How I treat acute myeloid leukemia.","volume":"116","author":"Rowe","year":"2010","journal-title":"Blood"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOH.0b013e3283257a87","article-title":"Second hematopoietic stem cell transplantation in myeloid malignancies.","volume":"16","author":"Arfons","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"R9-20250504","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12094-017-1798-8","article-title":"Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.","volume":"20","author":"Bao","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"R11-20250504","first-page":"571","article-title":"[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].","volume":"37","author":"Duan","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.clml.2017.09.007","article-title":"A phase II study of CLAG regimen combined with imatinib mesylate for relapsed or refractory acute myeloid leukemia.","volume":"17","author":"Mirza","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000493250","article-title":"Analysis of efficacy and prognostic factors of CLAG treatment in chinese patients with refractory or relapsed acute myeloid leukemia.","volume":"141","author":"Wang","year":"2019","journal-title":"Acta Haematol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","article-title":"Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","article-title":"A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).","volume":"71","author":"Wrzesie\u0144-Ku\u015b","year":"2003","journal-title":"Eur J Haematol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00277-016-2774-z","article-title":"Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.","volume":"95","author":"Park","year":"2016","journal-title":"Ann Hematol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","article-title":"Salvage chemotherapy regimens for acute myeloid leukemia: is one better? efficacy comparison between CLAG and MEC regimens.","volume":"35","author":"Price","year":"2011","journal-title":"Leuk Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e12102","DOI":"10.1097\/MD.0000000000012102","article-title":"Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: a retrospective cohort study.","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10428194.2020.1821009","article-title":"Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed\/refractory acute myeloid leukemia.","volume":"62","author":"Mushtaq","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/jcm9020536","article-title":"Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as first-line salvage cytotoxic chemotherapy for relapsed\/refractory acute myeloid leukemia.","volume":"9","author":"Patzke","year":"2020","journal-title":"J Clin Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00277-019-03723-w","article-title":"Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed\/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.","volume":"98","author":"Ye","year":"2019","journal-title":"Ann Hematol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"e1663","DOI":"10.1634\/theoncologist.2020-0818","article-title":"Cladribine with granulocyte colony-stimulating factor, cytarabine, and aclarubicin regimen in refractory\/relapsed acute myeloid leukemia: a phase II multicenter study.","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2019.236810","article-title":"Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.","volume":"105","author":"Abboud","year":"2020","journal-title":"Haematologica"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2018.204792","article-title":"Phase I\/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed\/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.","volume":"104","author":"Halpern","year":"2019","journal-title":"Haematologica"},{"key":"R25-20250504","first-page":"1563","article-title":"Clinical and laboratory studies of 2-chlorodeoxyadenosine +\/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.","volume":"10","author":"Kornblau","year":"1996","journal-title":"Leukemia"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/1042819021000054670","article-title":"In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential.","volume":"44","author":"Chow","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S207425","article-title":"Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis.","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.leukres.2013.12.010","article-title":"Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.","volume":"38","author":"Jaglal","year":"2014","journal-title":"Leuk Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428194.2021.1885654","article-title":"Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG \u00b1 M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.","volume":"62","author":"Przespolewski","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cncr.22471","article-title":"Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-c and imatinib.","volume":"109","author":"Heidel","year":"2007","journal-title":"Cancer"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00280-003-0668-y","article-title":"Avramis VI: determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and\/or STI571 (imatinib mesylate Gleevec) with cytotoxic drugs against human leukemia cell lines.","volume":"52","author":"Avramis","year":"2003","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:20:14Z","timestamp":1746325214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":32,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034949","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,11,3]]}}}